Share Name |
Share Symbol |
Market |
Type |
Share ISIN |
Share Description |
Netscientific Plc |
LSE:NSCI |
London |
Ordinary Share |
GB00BN4R5Q82 |
ORD 5P |
|
Price Change |
% Change |
Share Price |
Bid Price |
Offer Price |
High Price |
Low Price |
Open Price |
Shares Traded |
Last Trade |
|
0.50 |
1.03% |
49.00 |
48.00 |
50.00 |
49.00 |
48.50 |
48.50 |
44,036 |
15:33:18 |
Industry Sector |
Turnover (m) |
Profit (m) |
EPS - Basic |
PE Ratio |
Market Cap (m) |
Health Care Equipment & Services |
0.7 |
-3.6 |
-5.7 |
- |
7 |
Netscientific Share Discussion Threads

Showing 2651 to 2674 of 2675 messages
Date | Subject | Author | Discuss |
---|
14/1/2021 14:05 | Yep but need to see decent rise and stable increase. Been in this range way to long.... |  samsung2020 | |
14/1/2021 14:03 | PDS Biotech Releases White Paper Detailing the Potential of the Versamune(R) Platform in Overcoming a Major Limitation of Immuno-Oncology
Good news at last |  jerseysteve | |
06/1/2021 10:05 | Needs news mate, hopefully the stuff Brazil gets moving soon and this has a decent impact on NSCI. It's been super quiet on this stock since July so surely something soon - I hope :) |  samsung2020 | |
06/1/2021 09:55 | Talk about the quiet place! |  loafofbread | |
24/12/2020 10:34 | Hope so mate. Have a nice Xmas. |  samsung2020 | |
24/12/2020 10:31 | Just Proaxsis and PDSB cover our market cap imho, the rest is option money.
Concert party at 42% and placing at 65p gives direction of travel.
Expect some serious newsflow come the New Year. |  loafofbread | |
22/12/2020 22:49 | No doubt that is super cheap and when it does rise,multibag for sure at current rate. I've bought in a lot higher and would have liked it at least double of current price by now |  samsung2020 | |
22/12/2020 22:29 | I'm more than happy to be able to buy a worthwhile position at this price.
A bit like an investment trust, but 100%+ below NAV! |  loafofbread | |
22/12/2020 22:20 | Evening gents. Must confess, slightly disappointed we haven't seen a decent spike here in quite some time. Lots of time it's got going but not really materialised. Was hoping for close to 90p on Xmas day, don't see it now.... Interested in views.. |  samsung2020 | |
16/12/2020 10:37 | How, it would be 4.5p! It was a 10:1 |  charlie88888 | |
16/12/2020 09:04 | Now 2.3p old money - I think - e&oe - Confirmation please? |  pugugly | |
10/12/2020 07:25 | Great news Hopefully we see solid blue movement here today. |  samsung2020 | |
10/12/2020 07:17 | ProAxsis awarded Innovate UK grant.
Great news |  jerseysteve | |
06/12/2020 21:03 | Some chap on Twitter wrote this....#NSCI due a rise with $PDSB up 27% on Friday following a new broker target of $7:00. Recent placing in NSCI was 65p with multiple investments the cash and value of PDSB means no value attributed to any of there other companies. |  samsung2020 | |
04/12/2020 22:12 | PDSB lovely gap that needs closing between $3 and $4
I expect next major news challenge/take out $5 year high |  the stigologist | |
04/12/2020 15:39 | Will be over 60p xmas day |  professor_az | |
04/12/2020 15:39 | Finally a bit of blue |  blakieboy7 | |
04/12/2020 15:10 | PDSB now 26% up, surely we will see movement here asap |  samsung2020 | |
04/12/2020 15:03 | News from Brazil next week ? |  nextlink | |
03/12/2020 13:45 | ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
DECEMBER 2, 2020-POSTED BY DAVID RIBEIRO
ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it has been recognised as a Gold Level Innovator in the Innovate NI Innovation Accreditation programme. The company has been recognised due to it continually demonstrating its ability to transform innovate ideas into commercially successful products.
Speaking about the recognition, Dr David Ribeiro, CEO of ProAxsis, commented:
“Recognition of this kind from Innovate NI is a great testament to both the cutting-edge research being conducted by the ProAxsis team of scientists at our purpose-built laboratory in Belfast, and our ability to transition these exciting concepts in to commercially viable assets. ProAxsis has conducted a number of R&D projects supported by Invest Northern Ireland, which have successfully led to the launch of highly novel protease biomarker assays, and we remain extremely grateful for their ongoing support in propelling the company towards being a globally-renowned protease diagnostics company.”
Innovate NI is a Department for the Economy programme, helping local businesses innovate successfully. It is delivered by Invest Northern Ireland, local councils and further education colleges.
Dr Vicky Kell, Invest NI’s Director of Innovation, Research & Development, added: “Over the last 5 years, we have worked in partnership with ProAxsis and our innovation support, including R&D, has helped it to develop and bring to market new diagnostic products which are now sold globally. As this company has proven, innovation is the key to business resilience and growth and being recognised as a Gold level innovator is testament to the success of its innovation journey so far. With this commitment to innovation, I am confident ProAxsis will continue to develop ground-breaking diagnostics, ultimately benefiting patients around the World.”
Any enquiries concerning ProAxsis’ work on protease biomarkers can be directed to info@proaxsis.com.
About ProAxsis
ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis.
This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months.
In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha. Grant-funded R&D projects for a variety of targets remain a key area of focus.
Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials. |  loafofbread | |
02/12/2020 19:01 | Stuggy wat happen?this share is dead d0g |  prof_pwhite | |
30/11/2020 15:49 | What are u chatting about stiggybiggy |  prof_pwhite | |
30/11/2020 14:54 | There's a pulse
News on PDSB and Glycotest please thanks |  the stigologist | |